Package Leaflet: Information for the Patient
Ivabradine Tarbis Farma 5 mg film-coated tablets EFG
Ivabradine Tarbis Farma 7.5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Ivabradine Tarbis Farma is a heart medicine used to treat:
About stable angina pectoris (commonly known as "angina")
Stable angina pectoris is a heart disease that occurs when the heart does not receive enough oxygen. The most common symptom of angina is chest pain or discomfort.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
The specific action of ivabradine to reduce heart rate helps to:
Do not take Ivabradine Tarbis Farma
Warnings and precautions
Consult your doctor or pharmacist before starting to take ivabradine:
If you meet any of these conditions, consult your doctor immediately before or during treatment with ivabradine.
Children
Do not give this medicine to children and adolescents under 18 years of age.
Other medicines and Ivabradine Tarbis Farma
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Make sure to inform your doctor if you are taking any of the following medicines, as a dose adjustment of ivabradine or monitoring may be necessary:
Taking Ivabradine Tarbis Farma with food and drinks
Avoid grapefruit juice during treatment with ivabradine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take ivabradine if you are pregnant or planning to become pregnant (see "Do not take Ivabradine Tarbis Farma").
If you are pregnant and have taken ivabradine, consult your doctor.
Do not take ivabradine if you are of childbearing age and do not use reliable contraceptive methods (see "Do not take Ivabradine Tarbis Farma").
Do not take ivabradine if you are breastfeeding (see "Do not take Ivabradine Tarbis Farma"). Talk to your doctor if you are breastfeeding or planning to breastfeed, as breastfeeding should be discontinued if you are taking Ivabradine Tarbis Farma.
Driving and using machines
Ivabradine Tarbis Farma may cause transient visual phenomena (a transient brightness in the field of vision, see "Possible side effects"). If this happens to you, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
Ivabradine Tarbis Farma contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Ivabradine tablets should be taken with breakfast and dinner.
The tablet can be divided into two equal doses.
If you are being treated for stable angina pectoris
The initial dose should not exceed one 5 mg Ivabradine tablet twice a day. If you still have symptoms of angina and if you have tolerated the 5 mg dose twice a day well, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are 75 years or older), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradine tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one 5 mg Ivabradine tablet twice a day, which can be increased if necessary to one 7.5 mg Ivabradine tablet twice a day. Your doctor will decide the suitable dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are 75 years or older), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradine tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you take more Ivabradine Tarbis Farma than you should
An excessive dose of ivabradine may make you feel tired or have difficulty breathing because your heart is beating too slowly. If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Ivabradine Tarbis Farma
If you forget to take a dose of ivabradine, take the next dose at the scheduled time. Do not take a double dose to make up for forgotten doses.
The printed calendar on the blister pack containing the tablets will help you remember when you last took an ivabradine tablet.
If you stop taking Ivabradine Tarbis Farma
Generally, treatment for angina pectoris or chronic heart failure is for life, so you should consult your doctor before stopping this medicine.
If you think the action of Ivabradine Tarbis Farma is too strong or too weak, tell your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most common adverse reactions with this medicine are dose-dependent and are related to its mechanism of action:
Very common(may affect more than 1 in 10 people):
Transient visual phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). They can also be described as a halo, flashes of color, decomposition of the image, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common(may affect up to 1 in 10 people):
Modification of heart function (the symptoms are a slowing of the heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common(may affect up to 1 in 10 people):
Rapid irregular heart contraction (atrial fibrillation), sensation of abnormal heartbeat (bradycardia, ventricular extrasystoles, first-degree AV block (prolongation of the PQ interval in the ECG)), uncontrolled high blood pressure, headache, dizziness, and blurred vision (cloudy vision).
Uncommon(may affect up to 1 in 100 people):
Palpitations and extra heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle cramps, changes in laboratory tests: elevated blood uric acid levels, excess eosinophils (a type of white blood cell), and elevated creatinine levels in blood (a muscle breakdown product), skin rash, angioedema (such as facial swelling, tongue or throat swelling, difficulty breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal electrocardiogram, double vision, visual disturbance.
Rare(may affect up to 1 in 1,000 people):
Hives, itching, skin redness, malaise.
Very rare(may affect up to 1 in 10,000 people):
Irregular heartbeats (second-degree AV block, third-degree AV block, sick sinus syndrome).
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, after EXP. The expiry date is the last day of the month shown.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Ivabradine Tarbis Farma
The active substance is ivabradine (as hydrochloride).
Each film-coated tablet contains 5 mg of ivabradine (equivalent to 5.390 mg of ivabradine hydrochloride).
Each film-coated tablet contains 7.5 mg of ivabradine (equivalent to 8.085 mg of ivabradine hydrochloride).
The other ingredients are:
Core of the tablet:
Lactose monohydrate, corn starch, maltodextrin, colloidal anhydrous silica, magnesium stearate.
Coating material:
5 mg:
Hypromellose (2910 6 mPa.s) (E464), titanium dioxide (E171), macrogol 6000 (E1521), glycerol (E422), magnesium stearate (E470b).
7.5 mg:
Hypromellose (2910 6 mPa.s) (E464), titanium dioxide (E171), macrogol 6000 (E1521), glycerol (E422), yellow iron oxide (E172), black iron oxide (E172), red iron oxide (E172), magnesium stearate (E470b)
Appearance of the product and contents of the pack
Ivabradine Tarbis Farma 5 mg film-coated tablets EFG
Film-coated tablet, oval-shaped, white to off-white, scored on both edges, engraved with a "V" on one side and "9" divided by "1" on the other side.
The tablet can be divided into two equal doses.
Ivabradine Tarbis Farma 7.5 mg film-coated tablets EFG
Film-coated tablet, brown, oval-shaped, engraved with "V" on one face and "92" on the other.
The tablets are available in blisters of 28, 56, and 98 tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Tarbis Farma S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Spain
Manufacturer
Amarox Pharma B.V.
Rouboslaan 32
Voorschoten, 2252TR
Netherlands
This medicine is authorised in the Member States of the European Economic Area under the following names:
Germany: Ivabradine Amarox 5 mg/7.5 mg film-coated tablets
Netherlands: Ivabradine Amarox 5 mg/7.5 mg film-coated tablets
Spain: Ivabradina Tarbis Farma 5 mg/7.5 mg film-coated tablets EFG
Date of last revision of this leaflet:February 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/